Charles Bankhead
MedPage Today
Houston, TX, United States
Contact Charles
Discover and connect with journalists and influencers around the world, save time on email research, monitor the news, and more.
| Recent: |
|
| Past: |
|
Past articles by Charles:
FDA OKs First Novel Nonsteroidal Topical for Plaque Psoriasis in 25 Years
Complete, near-complete clearance in 35-40% of patients treated with tapinarof cream 1% → Read More
Year in Review: HER2-Positive Breast Cancer
ADCs impress in second-line therapy, primary surgery debate, neoadjuvant PD-L1 falls short → Read More
FDA OKs Virtual-Reality Device to Correct Vision Disorder in Kids
Luminopia One doubled vision gain in amblyopia versus eyeglasses → Read More
Clinical Challenge: Managing Pain in Hidradenitis Suppurativa
Achieving pain control in a patient population with an increased risk of substance use → Read More
FDA Approves CAR T-Cell Therapy for Multiple Myeloma
Idecabtagene vicleucel led to objective responses in 72% of heavily treated patients → Read More
Peptide-Drug Conjugate Active in R/R Myeloma
Responses in 29% of heavily treated patients with melflufen and dexamethasone → Read More
Nonsteroidal Topical, Nanodrug Active in Psoriasis
Selected presentations from the European Academy of Dermatology and Venereology meeting → Read More
Best Cancer Prevention Data Yet for HPV Vaccine
As much as 88% reduction in cervical cancer risk linked with vaccine uptake in Sweden → Read More
Recent Cancer Diagnoses Far Short of Expectation
Dark omen for people who skipped screenings or ignored symptoms during pandemic → Read More
Cancer and COVID-19; Breast Cancer Progress; RT for Women: Good News, Bad News
News, features, and commentary about cancer-related issues → Read More
COVID-19 Update: We're No. 1; Aircraft Carrier at Risk; No Ventilator Sharing?
A daily roundup of news on the novel coronavirus outbreak → Read More
Study: Most With Early DLBCL Can Skip RT
Chemoimmunotherapy appears sufficient for patients with PET-negative interval scans → Read More
Cautionary Data on Rapid Opioid Tapering
Tapering protocols exceeded recommended maximum in almost 20% of cases → Read More
Ovarian Cancer Drug Misses Mark... Right?
Anti-folate fails phase III test, but key biomarker measurement may have been faulty → Read More
Good Early Results With Laser for Chronic Rhinitis
Durable effects with no bleeding, crusting, or laser-related complications → Read More
Hope and Cancer; Two-for-One Cancer Test; Realities of Stage IV Disease
News, features, and commentary about cancer-related issues → Read More
First Oncology Biosimilars Reach U.S. Market
Bevacizumab-awwb, trastuzumab-anns priced 12-15% below originals → Read More
ADC-Based Regimen Gets FDA Nod for DLBCL
Polatuzumab vedotin plus bendamustine and rituximab for relapsed/refractory disease → Read More
First PI3K Inhibitor Wins FDA Approval in Breast Cancer
Alpelisib plus fulvestrant OK'd for advanced PIK3CA-mutated disease → Read More
Recent Developments in Breast Cancer
Immunotherapy, PI3K inhibitor breakthroughs, skipping chemo in HER2-positive disease → Read More